Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Contact Us
  • Investors

In The News

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
February 6, 2023

Ensysce Biosciences: A Solution to the Opioid Crisis?

December 15, 2022

As We Enter “the Most Dangerous Time of the Year”, a Solution to Prescription Opioid Overdose may be in Sight

November 9, 2022

Dr. Vince Clinical Research Announces Dosing of Ensysce's PF614 Compound in Human Abuse Potential Trial

September 26, 2022

Women in Pharma: Ensysce Biosciences’ CEO aims to combat prescription drug abuse

September 23, 2022

Ensysce Featured on Benzinga All Access

September 6, 2022

Ensysce Biosciences’ transformative chemistry targeting drug safety and performance

August 15, 2022

Thought Leader, Dr. Lynn Kirkpatrick Discusses a New Class of Prescription Drugs Designed to Defeat Abuse & Overdose

rss_feed RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio